オプションチェーンは、Adaptive Biotechnologiesの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Adaptive Biotechnologiesの市場センチメントを評価します。.

Adaptive Biotechnologies (NASDAQ:ADPT) 株価情報, オプションチェーン

Adaptive Biotechnologies

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Adeptus Health

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies Corp

On Friday, Cathie Wood-led Ark Invest made significant trades involving Beam Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), Nu Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>), MercadoLibre Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>), and Adaptive Biotechnologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>).
The BEAM Trade
Ark Invest, through its ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) and ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>), bought a total of 24,640 shares of Beam Therapeutics.
This comes after the firm&#8217;s <a href="https://www.benzinga.com/25/02/43755344/cathie-woods-ark-invest-loads-up-on-iridium-twist-bioscience-offloads-roku-here-are-key-ark-trades-this-friday">previous acquisition</a> of Beam Therapeutics shares just a week prior. The value of this trade, calculated from the latest closing price is nearly $750,000.
The NU Trade
Ark Invest, through its ARK Fintech Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>), bought 162,143 shares of Nu Holdings Ltd. This marks a significant investment in the fintech company, reflecting Ark&#8217;s strategic positioning in the dynamic tech sector.
The value of this trade, calculated from the latest closing price is over $1.75 million.
The MELI and ADPT Trades
On the same day, Ark Invest also sold shares of MercadoLibre Inc and Adaptive Biotechnologies Corp. Through its ARK Fintech Innovation ETF, Ark sold 347 shares of MercadoLibre.
Meanwhile, through its ARK Genomic Revolution ETF, Ark offloaded 8,129 shares of Adaptive Biotechnologies.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43900360/bill-gates-has-a-warning-for-the-next-generation-says-be-very-afraid-of-these-4-issues">Bill Gates Has A Warning For The Next Generation, Says Be ‘Very Afraid&#8217; Of These 4 Issues</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Ark Invest

Equities

News

Markets

ETFs

ADPT

ARKF

ARKG

ARKK

BEAM

MELI

Cathie Wood's Ark Invest Loads Up On Beam Therapeutics, Nu Holdings: Offloads MercadoLibre, Adaptive Biotechnologies

Piper Sandler analyst David Westenberg reiterates Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) with a Overweight and raises the price target from $7 to $11.

Price Target

Reiteration

Analyst Ratings

Piper Sandler Reiterates Overweight on Adaptive Biotechnologies, Raises Price Target to $11

Scotiabank analyst Sung Ji Nam maintains Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) with a Sector Outperform and raises the price target from $10 to $12.

Scotiabank Maintains Sector Outperform on Adaptive Biotechnologies, Raises Price Target to $12

WIIM

Adaptive Biotechnologies shares are trading lower. The company reported Q4 financial results.

Guidance

Adaptive Biotechnologies Sees FY25 Revenue For MRD Business $175M-$185M

Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.26) by 11.54 percent. The company reported quarterly sales of $47.459 million which beat the analyst consensus estimate of $46.034 million by 3.09 percent. This is a 3.66 percent increase over sales of $45.784 million the same period last year.

Earnings

Earnings Beats

Adaptive Biotechnologies Q4 2024 GAAP EPS $(0.23) Beats $(0.26) Estimate, Sales $47.459M Beat $46.034M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) is estimated to report quarterly earnings at $1.05 per share on revenue of $743.60 million. 
• AutoNation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AN#NYSE">AN</a>) is likely to report quarterly earnings at $4.26 per share on revenue of $6.81 billion. 
• Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) is estimated to report quarterly loss at $2.12 per share on revenue of $28.84 billion. 
• Carrier Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) is projected to report quarterly earnings at $0.48 per share on revenue of $5.20 billion. 
• DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) is projected to report quarterly earnings at $0.98 per share on revenue of $3.07 billion. 
• BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $45.65 billion. 
• Yatra Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YTRA#NASDAQ">YTRA</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $15.02 million. 
• NNN REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>) is estimated to report quarterly earnings at $0.82 per share on revenue of $217.60 million. 
• OrganiGram Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) is projected to report quarterly loss at $0.03 per share on revenue of $48.93 million. 
• Arvinas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) is estimated to report quarterly loss at $1.04 per share on revenue of $59.49 million. 
• Orion Energy Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OESX#NASDAQ">OESX</a>) is expected to report quarterly loss at $0.01 per share on revenue of $26.52 million. 
• Jerash Holdings (US) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRSH#NASDAQ">JRSH</a>) is expected to report quarterly loss at $0.01 per share on revenue of $37.65 million. 
• Ceragon Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNT#NASDAQ">CRNT</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $105.16 million. 
• SolarWinds (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWI#NYSE">SWI</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $202.91 million. 
• Curbline Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURB#NYSE">CURB</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $28.88 million. 
• IPG Photonics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPGP#NASDAQ">IPGP</a>) is projected to report quarterly earnings at $0.22 per share on revenue of $229.47 million. 
• LCI Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LCII#NYSE">LCII</a>) is projected to report quarterly earnings at $0.31 per share on revenue of $799.81 million. 
• Sequans Communications (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQNS#NYSE">SQNS</a>) is likely to report quarterly loss at $0.07 per share on revenue of $10.50 million. 
• Sunoco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUN#NYSE">SUN</a>) is likely to report quarterly earnings at $1.34 per share on revenue of $5.92 billion. 
• WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $650.00 million. 
• Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) is projected to report quarterly earnings at $1.36 per share on revenue of $2.63 billion. 
• Marriott Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) is likely to report quarterly earnings at $2.36 per share on revenue of $6.39 billion. 
• MYT Netherlands Parent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYTE#NYSE">MYTE</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $217.77 million. 
• Shopify (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) is projected to report quarterly earnings at $0.43 per share on revenue of $2.73 billion. 
• WESCO Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCC#NYSE">WCC</a>) is expected to report quarterly earnings at $3.23 per share on revenue of $5.42 billion. 
• TPG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) is projected to report quarterly earnings at $0.52 per share on revenue of $463.18 million. 
• USA Compression Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USAC#NYSE">USAC</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $242.95 million. 
• S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) is projected to report quarterly earnings at $3.41 per share on revenue of $3.46 billion. 
• Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $10.70 billion. 
• Leidos Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) is projected to report quarterly earnings at $2.27 per share on revenue of $4.13 billion. 
• Masco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) is estimated to report quarterly earnings at $0.87 per share on revenue of $1.84 billion. 
• GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $1.83 billion. 
• Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) is expected to report quarterly earnings at $1.81 per share on revenue of $4.03 billion. 
<h3>Companies Reporting After The Bell</h3>
• Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is likely to report quarterly earnings at $1.70 per share on revenue of $7.15 billion. 
• Monarch Casino &amp; Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRI#NASDAQ">MCRI</a>) is projected to report quarterly earnings at $1.06 per share on revenue of $129.03 million. 
• Avis Budget Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) is projected to report quarterly loss at $1.03 per share on revenue of $2.73 billion. 
• Franklin Street Props (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FSP#AMEX">FSP</a>) is projected to report quarterly loss at $0.07 per share on revenue of $30.83 million. 
• Edwards Lifesciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) is projected to report quarterly earnings at $0.55 per share on revenue of $1.49 billion. 
• Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) is projected to report quarterly earnings at $0.63 per share on revenue of $5.78 billion. 
• Evolution Petroleum (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EPM#AMEX">EPM</a>) is likely to report quarterly earnings at $0.02 per share on revenue of $22.73 million. 
• Bioceres Crop Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOX#NASDAQ">BIOX</a>) is expected to report quarterly earnings at $0.15 per share on revenue of $144.62 million. 
• Genasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNSS#NASDAQ">GNSS</a>) is projected to report quarterly loss at $0.16 per share on revenue of $6.59 million. 
• Everus Construction Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECG#NYSE">ECG</a>) is expected to report earnings for its fourth quarter. 
• United Fire Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UFCS#NASDAQ">UFCS</a>) is likely to report quarterly earnings at $0.66 per share on revenue of $327.70 million. 
• Tigo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYGO#NASDAQ">TYGO</a>) is estimated to report quarterly loss at $0.16 per share on revenue of $15.62 million. 
• HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $28.48 million. 
• Atomera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOM#NASDAQ">ATOM</a>) is likely to report quarterly loss at $0.14 per share on revenue of $500 thousand. 
• Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) is projected to report quarterly loss at $1.38 per share on revenue of $14.11 million. 
• Exelixis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) is expected to report quarterly earnings at $0.48 per share on revenue of $562.72 million. 
• Forrester Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORR#NASDAQ">FORR</a>) is projected to report quarterly earnings at $0.34 per share on revenue of $106.25 million. 
• BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) is projected to report quarterly earnings at $0.50 per share on revenue of $168.10 million. 
• Primerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>) is likely to report quarterly earnings at $4.90 per share on revenue of $766.63 million. 
• Allison Transmission (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>) is likely to report quarterly earnings at $1.91 per share on revenue of $765.40 million. 
• Electromed (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ELMD#AMEX">ELMD</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $15.30 million. 
• W.P. Carey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPC#NYSE">WPC</a>) is estimated to report quarterly earnings at $1.20 per share on revenue of $397.32 million. 
• Sensata Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) is estimated to report quarterly earnings at $0.75 per share on revenue of $883.43 million. 
• Pitney Bowes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBI#NYSE">PBI</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $509.65 million. 
• America Movil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMX#NYSE">AMX</a>) is expected to report quarterly earnings at $0.38 per share on revenue of $12.27 billion. 
• Eversource Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ES#NYSE">ES</a>) is expected to report quarterly earnings at $1.02 per share on revenue of $3.13 billion. 
• Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) is expected to report quarterly loss at $0.24 per share on revenue of $45.84 million. 
• Anterix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEX#NASDAQ">ATEX</a>) is expected to report quarterly loss at $0.61 per share on revenue of $1.88 million. 
• IAC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) is likely to report quarterly earnings at $0.39 per share on revenue of $934.31 million. 
• Mercury General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCY#NYSE">MCY</a>) is estimated to report quarterly earnings at $0.64 per share on revenue of $1.23 billion. 
• American Intl Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>) is expected to report quarterly earnings at $1.53 per share on revenue of $6.70 billion. 
• Diodes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIOD#NASDAQ">DIOD</a>) is estimated to report quarterly earnings at $0.32 per share on revenue of $337.10 million. 
• Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) is projected to report quarterly loss at $0.01 per share on revenue of $1.55 billion. 
• Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $532.04 million. 
• Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $533.26 million. 
• Teradata (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDC#NYSE">TDC</a>) is projected to report quarterly earnings at $0.44 per share on revenue of $417.67 million. 
• DoubleDown Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDI#NASDAQ">DDI</a>) is projected to report quarterly earnings at $0.58 per share on revenue of $85.54 million. 
• Similarweb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMWB#NYSE">SMWB</a>) is likely to report quarterly earnings at $0.03 per share on revenue of $65.48 million. 
• OneStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>) is likely to report quarterly earnings at $0.02 per share on revenue of $128.13 million. 
• MRC Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRC#NYSE">MRC</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $726.90 million. 
• Mirion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MIR#NYSE">MIR</a>) is estimated to report quarterly earnings at $0.15 per share on revenue of $245.02 million. 
• Upstart Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $181.92 million. 
• Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) is projected to report quarterly earnings at $1.12 per share on revenue of $2.12 billion. 
• Silvercorp Metals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SVM#AMEX">SVM</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $80.90 million. 
• Kite Realty Gr Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRG#NYSE">KRG</a>) is projected to report quarterly earnings at $0.53 per share on revenue of $209.12 million. 
• Gladstone Cap (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLAD#NASDAQ">GLAD</a>) is likely to report quarterly earnings at $0.53 per share on revenue of $24.40 million. 
• InvenTrust Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVT#NYSE">IVT</a>) is likely to report quarterly earnings at $0.41 per share on revenue of $71.16 million. 
• Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $254.21 million. 
• Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) is projected to report quarterly earnings at $0.38 per share on revenue of $21.43 million. 
• Red Rock Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>) is projected to report quarterly earnings at $0.52 per share on revenue of $491.36 million. 
• Assurant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>) is likely to report quarterly earnings at $3.51 per share on revenue of $3.08 billion. 
• Acadia Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKR#NYSE">AKR</a>) is likely to report quarterly earnings at $0.33 per share on revenue of $83.33 million. 
• Brighthouse Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>) is estimated to report quarterly earnings at $4.58 per share on revenue of $2.22 billion. 
• Highwoods Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIW#NYSE">HIW</a>) is projected to report quarterly earnings at $0.86 per share on revenue of $203.87 million. 
• Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) is estimated to report quarterly earnings at $0.10 per share on revenue of $189.30 million. 
• DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) is projected to report quarterly earnings at $0.33 per share on revenue of $2.84 billion. 
• Agree Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>) is projected to report quarterly earnings at $1.03 per share on revenue of $156.13 million. 
• Confluent (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $256.84 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALSN

ANGI

ARVN

ATEX

ATOM

Brighthouse Financial, Inc. - Common Stock

BIOX

CARR

CFLT

CRNT

CURB

DASH

DIOD

ELMD

EXEL

FORR

FRSH

GILD

GLAD

GNSS

HIVE

IPGP

JRSH

LCII

LDOS

LYFT

MCRI

MYTE

OESX

RPRX

SAGE

SHOP

SMCI

SMWB

SPGI

SQNS

TYGO

UFCS

UPST

USAC

WELL

YTRA

Earnings Scheduled For February 11, 2025

Goldman Sachs analyst Salveen Richter maintains Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) with a Neutral and raises the price target from $5.5 to $7.5.

Goldman Sachs Maintains Neutral on Adaptive Biotechnologies, Raises Price Target to $7.5

Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>), a leading oncology testing services company, today announced a multi-year exclusive strategic commercial collaboration that will advance minimal residual disease (MRD) monitoring options for patients with select blood cancers.

Adaptive Biotechnologies and NeoGenomics Partner to Enhance MRD Monitoring for Blood Cancer Patients

On Monday, Cathie Wood-led Ark Invest made significant trades in five major companies: Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), Tempus AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), CareDx Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), Veracyte Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), Adaptive Biotechnologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>).
The PLTR Trade
Ark Invest&#8217;s Ark Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) fund sold 140,518 shares of Palantir. This move is significant, considering Ark Invest&#8217;s&nbsp;<a href="https://www.benzinga.com/25/01/42865484/cathie-woods-tuesday-double-dump-ark-invest-trims-both-palantir-and-bitcoin-etf-holdings">recent trend of offloading Palantir shares</a>.
The total value of this trade, based on the latest closing price of $64.98, is approximately $9.1 million.
This sale follows Ark&#8217;s disposal of shares worth roughly $15 million the previous week.
Palantir stock price has fallen more than 14% over the past month. In just the first two weeks of 2025, the stock has declined nearly 15%.
The TEM Trade
Ark Invest&#8217;s ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) and ARKK funds made substantial purchases of Tempus AI Inc. shares. The ARKG fund bought 98,691 shares, while the ARKK fund purchased a whopping 280,192 shares.
Given the latest closing price of $32.34, the total value of these trades amounts to approximately $12.2 million.
This move comes amid TEM&#8217;s 13.81% drop on Monday.
Other Key Trades:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>ETF</td>
<td>Transaction</td>
<td>No. Of Shares</td>
<td>Closing price</td>
<td>Approx. Value</td>
</tr>
<tr>
<td>Veracyte Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>)</td>
<td>ARK Genomic Revolution</td>
<td>Sale</td>
<td>37,358</td>
<td>$42.78</td>
<td>$1.6 million</td>
</tr>
<tr>
<td>Adaptive Biotechnologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>)</td>
<td>ARK Genomic Revolution</td>
<td>Sale</td>
<td>76,522</td>
<td>$6.46</td>
<td>$494,332</td>
</tr>
<tr>
<td>CareDx Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>)</td>
<td>ARK Genomic Revolution</td>
<td>Sale</td>
<td>65,550</td>
<td>$25.07</td>
<td>$1.6 million</td>
</tr>
</tbody>
</table>
</figure>
Closing price as of Jan. 13, 2025
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42931941/mark-zuckerberg-critiques-culturally-neutered-companies-advocates-for-masculine-energy-as-meta-cuts-dei-programs-post-joe-rogan-appearance">Mark Zuckerberg Critiques &#8216;Culturally Neutered&#8217; Companies, Advocates For &#8216;Masculine Energy&#8217; As Meta Cuts DEI Programs Post-Joe Rogan Appearance</a></li>
</ul>
Image via Benzinga YouTube and Unsplash
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/Rounak-Jain" target="_blank" rel="noreferrer noopener">Rounak Jain</a>

Tech

CDNA

PLTR

VCYT

Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025

Cathie Wood-led&nbsp;Ark Invest&nbsp;made significant trades in five major companies on Friday: Recursion Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), Intellia Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), Cloudflare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>), and Adaptive Biotechnologies Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>).
The RXRX Trade
Ark Invest&#8217;s ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) purchased a substantial 264,596 shares of&nbsp;Recursion Pharmaceuticals.
The value of this trade, calculated from the closing price of $6.88, is approximately $1.82 million. This move comes despite RXRX&#8217;s stock closing at a 5.23% decrease on Friday.
The ILMN Trade
Ark Invest&#8217;s Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) and ARK Innovation ETF both bought shares of&nbsp;Illumina Inc.
ARKG acquired 4038 shares, while ARKK purchased 11425 shares. The combined value of these trades, calculated from the closing price of $136.69, is approximately $1.97 million.
This move was made despite Illumina's stock closing at a 2.14% decrease on Friday.
See Also: <a href="https://www.benzinga.com/25/01/42931747/bitcoin-supercycle-incoming-says-economist-but-theres-a-catch">Bitcoin Supercycle Incoming, Says Economist, But There&#8217;s A Catch</a>
The NTLA Trade
Ark Invest&#8217;s Genomic Revolution ETF and ARK Innovation ETF both bought shares of&nbsp;Intellia Therapeutics.
ARKG acquired 41503 shares, while ARKK purchased 124799 shares.
The combined value of these trades, calculated from the closing price of $10.2, is approximately $1.46 million. This move was made despite NTLA&#8217;s stock closing at a 15.14% decrease on Friday.
Intellia Therapeutics announced a 27% workforce reduction on Friday to cut costs.
The NET Trade
Ark Invest&#8217;s Next Generation Internet ETF (ARKW) sold 7840 shares of&nbsp;Cloudflare.
The value of this trade, calculated from the closing price of $112.62, is approximately $882,608. This move was made despite NET&#8217;s stock closing at a 2.66% decrease on Friday.
The ADPT Trade
Ark Invest&#8217;s Genomic Revolution ETF sold 130,790 shares of&nbsp;Adaptive Biotechnologies.
The value of this trade, calculated from the closing price of $6.5, is approximately $850,135. This move was made despite ADPT&#8217;s stock closing at a 2.84% decrease on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42931941/mark-zuckerberg-critiques-culturally-neutered-companies-advocates-for-masculine-energy-as-meta-cuts-dei-programs-">Mark Zuckerberg Critiques &#8216;Culturally Neutered&#8217; Companies, Advocates For &#8216;Masculine Energy&#8217; As Meta Cuts DEI Programs Post-Joe Rogan Appearance</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Ark Invest

ILMN

NTLA

RXRX

Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce

BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) with a Buy and raises the price target from $8 to $9.

BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $9

As of Dec. 11, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Adaptive Biotechnologies Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>)</h3>
<ul>
<li>On Dec. 7, Adaptive Biotechnologies presented new data at ASH 2024 showcasing clonoSEQ MRD testing advances and its role in guiding blood cancer treatment decisions. The company's shares gained around 6% over the past month and has a <a href="https://www.benzinga.com/quote/ADPT">52-week high of $7.07</a>.</li>
<li>RSI Value: 75.83&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>ADPT Price Action: Shares of Adaptive Biotechnologies gained 4.2% to close at $6.71 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">NewAmsterdam Pharma Company NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>)</h3>
<ul>
<li>On Dec. 10, NewAmsterdam Pharma revealed topline data from its Phase 3 BROADWAY clinical trial evaluating obicetrapib in adult patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. The company's stock gained around 30% over the past five days and <a href="https://www.benzinga.com/quote/NAMS">has a 52-week high</a> of $26.36.</li>
<li>RSI Value: 81.17</li>
<li>NAMS Price Action: Shares of NewAmsterdam Pharma jumped 41.4% to close at $26.19 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Paragon 28 Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNA#NYSE">FNA</a>)</h3>
<ul>
<li>On Nov. 12, Paragon 28 reported quarterly losses of 15 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $62.30 million which beat the analyst consensus estimate of $60.58 million. The company's stock gained around 38% over the past month and has a <a href="https://www.benzinga.com/quote/FNA">52-week high</a> of $14.79.</li>
<li>RSI Value: 77.07</li>
<li>FNA Price Action: Shares of Paragon 28 gained 5% to close at $10.50 on Tuesday. </li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42429201/dow-falls-for-4th-straight-session-alphabet-surges-on-google-quantum-chip-announcement-fear-greed-index-remains-in-neutral-zone">Dow Falls For 4th Straight Session, Alphabet Surges On Google Quantum Chip Announcement: Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Trading Ideas

NAMS

Top 3 Health Care Stocks That May Collapse This Quarter

<ul>
<li>New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL</li>
<li>Studies show depth of response at 10-6 provides more accurate assessment of treatment responses</li>
</ul>

Reported Saturday, Adaptive Biotechnologies Presented New Data at ASH 2024 Showcasing clonoSEQ MRD Testing Advances And Its Role In Guiding Blood Cancer Treatment Decisions

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.
What Happened: Wood&#8217;s enthusiasm centers on what she describes as a transformative convergence of technologies that could revolutionize medical treatment and drug discovery. 
Speaking candidly about the sector, Wood highlighted the remarkable progress in genetic therapies, particularly in companies like Crispr Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>), Intellia Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), and Beam Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>).
Her most striking example involves Crispr Therapeutics&#8217; recent breakthrough in sickle cell disease treatment. Wood noted, referencing how patients who previously required 12 to 20 annual blood transfusions might now be free from such interventions.
The strategy extends beyond treatment breakthroughs to drug development itself. Wood points to companies like Recursion Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) as leveraging artificial intelligence to dramatically reduce clinical trial failure rates and accelerate drug development timelines.
However, the market performance of these innovative companies tells a more nuanced story. Year-to-date, the stocks have experienced significant volatility: Crispr Therapeutics is down 25.36%, Intellia Therapeutics has dropped 52.21%, Beam Therapeutics declined 3.04%, and Recursion Pharmaceuticals fell 9.80%, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Which market sector excites <a href="https://twitter.com/CathieDWood?ref_src=twsrc%5Etfw">@CathieDWood</a> the most and why? In <a href="https://twitter.com/hashtag/askARK?src=hash&amp;ref_src=twsrc%5Etfw">#askARK</a>, she shares her growing enthusiasm for the biologics space. Have more questions for Cathie? Share them in the comments. <a href="https://t.co/WjilZChce6">pic.twitter.com/WjilZChce6</a>
&mdash; ARK Invest (@ARKInvest) <a href="https://twitter.com/ARKInvest/status/1861431767506268404?ref_src=twsrc%5Etfw">November 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/general/entertainment/24/11/42205763/disney-reaches-43m-settlement-in-gender-pay-discrimination-lawsuit-women-can-expect-equitable-treatment-moving-forward">Disney Reaches $43M Settlement In Gender Pay Discrimination Lawsuit: &#8216;Women Can Expect Equitable Treatment&#8217; Moving Forward</a>
Why It Matters: ARK&#8217;s commitment to this sector is evident through its Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>), which manages net assets of $1.179 billion. The fund&#8217;s performance reflects the sector&#8217;s volatility, with annual returns ranging from a high of 180.50% in 2020 to a low of -53.94% in 2022.
The ETF&#8217;s current top holdings underscore Wood&#8217;s strategic focus on innovative biological technologies. Twist Bioscience Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) leads the portfolio at 8.90%, followed by Crispr Therapeutics at 7.88% and Recursion Pharmaceuticals at 6.17%. Other significant investments include CareDx Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), Veracyte Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCYT#NASDAQ">VCYT</a>), and Adaptive Biotechnologies Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>), representing a diversified approach to genomic and biological innovation.
Wood&#8217;s vision suggests a potential $400 billion market opportunity in biologics over the next five years, driven by the unprecedented convergence of AI, sequencing technologies, and gene editing. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42202496/goldman-sachs-expects-major-selloffs-in-canadian-dollar-mexican-peso-says-trump-tariffs-threaten-usmca-agreement">Goldman Sachs Expects Major Selloffs In Canadian Dollar, Mexican Peso, Says Trump Tariffs Threaten USMCA Agreement</a></li>
</ul>
Image via Ark Invest
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Biotech

Health Care

CRSP

TWST

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?

Adaptive Biotechnologies shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $6 to $7.

Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) with a Overweight and raises the price target from $6 to $7.

Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $7

Adaptive Biotechnologies shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance.

Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.29) by 24.14 percent. The company reported quarterly sales of $46.435 million which beat the analyst consensus estimate of $40.208 million by 15.49 percent. This is a 22.46 percent increase over sales of $37.919 million the same period last year.

Adaptive Biotechnologies Q3 2024 GAAP EPS $(0.22) Beats $(0.29) Estimate, Sales $46.435M Beat $40.208M Estimate

Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) raises FY2024 sales outlook from $140.00 million-145.00 million to $143.00 million-145.00 million.

Adaptive Biotechnologies Raises FY2024 Sales Guidance from $140.00M-145.00M to $143.00M-145.00M

Press Releases

Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results

General

Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

Small Cap

Opinion

Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

ELEV

ONCY

ORIC

TSX:ONC

Agilent Technologies

AbCellera Biologics

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Adaptive Biotechnologies

Adaptive Biotechnologies (ADPT) オプション

Adaptive Biotechnologies (NASDAQ:ADPT) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル